Cargando…

Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study

BACKGROUND: Multimorbidity is a prevalent risk factor for COVID-19–related complications and death. We sought to evaluate the association of homologous booster vaccination using BNT162b2 (Pfizer-BioNTech) or CoronaVac (Sinovac) with COVID-19–related deaths among people with multimorbidity during the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Francisco Tsz Tsun, Yan, Vincent Ka Chun, Ye, Xuxiao, Ma, Tiantian, Qin, Xiwen, Chui, Celine Sze Ling, Li, Xue, Wan, Eric Yuk Fai, Wong, Carlos King Ho, Cheung, Ching Lung, Li, Philip Hei, Cheung, Bernard Man Yung, Lau, Chak Sing, Wong, Ian Chi Kei, Chan, Esther Wai Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Impact Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888544/ https://www.ncbi.nlm.nih.gov/pubmed/36717123 http://dx.doi.org/10.1503/cmaj.221068

Ejemplares similares

Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic
por: Huang, Lei, et al.
Publicado: (2022)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study
por: Fan, Min, et al.
Publicado: (2023)

Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
por: Cheng, Franco Wing Tak, et al.
Publicado: (2022)

COVID‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study
por: Sing, Chor‐Wing, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case–control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study
por: Chui, Celine Sze Ling, et al.
Publicado: (2022)

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)
por: Li, Xue, et al.
Publicado: (2023)

Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5–17
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2023)

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

Chronic Spontaneous Urticaria in Hong Kong: Clinical Characteristics, Real-World Practice and Implications for COVID-19 Vaccination
por: Kan, Andy Ka Chun, et al.
Publicado: (2022)

Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested case-control study
por: Ye, Xuxiao, et al.
Publicado: (2023)

Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK
por: Lam, Ivan Chun Hang, et al.
Publicado: (2023)

Adverse event reporting and Bell's palsy risk after COVID-19 vaccination – Authors' reply
por: Wong, Ian Chi Kei, et al.
Publicado: (2021)

Association between the risk of seizure and COVID‐19 vaccinations: A self‐controlled case‐series study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2022)

Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study
por: Chan, Edward Wai Wa, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study
por: Xiong, Xi, et al.
Publicado: (2023)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
por: Lai, Kristi Tsz-Wan, et al.
Publicado: (2022)

Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Efficacy and effectiveness of inactivated vaccines against symptomatic COVID-19, severe COVID-19, and COVID-19 clinical outcomes in the general population: a systematic review and meta-analysis
por: Law, Martin, et al.
Publicado: (2023)

Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases
por: Cheung, Carmen Ka Man, et al.
Publicado: (2023)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_43mk4m6n4o8n1vcegd5100kvj7